Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.
- Author:
Hyojin KIM
1
;
Hyo Sup SHIM
;
Lucia KIM
;
Tae Jung KIM
;
Kun Young KWON
;
Geon Kook LEE
;
Jin Haeng CHUNG
Author Information
1. Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. chungjh@snu.ac.kr gklee@ncc.re.kr
- Publication Type:Review
- Keywords:
Anaplastic lymphoma kinase;
Gene rearrangement;
Lung neoplasms;
Guideline
- MeSH:
Biopsy;
Diagnosis;
Gene Rearrangement*;
Humans;
Lung Neoplasms*;
Lung*;
Lymphoma;
Pathology*;
Phosphotransferases;
Prevalence;
Protein-Tyrosine Kinases
- From:Korean Journal of Pathology
2014;48(1):1-9
- CountryRepublic of Korea
- Language:English
-
Abstract:
Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
